Who wins: mega-check muscle or platform-seed patience?

Full breakdown, tables, and the ShAbbVie inversion that almost was: www.bigpharmasharma.com/p/changing-o...

Rick Gonzalez burned > $100 B on splashy “WTF” acquisitions like Allergan & ImmunoGen.
New skipper Rob Michael? He’s firing cheaper shots-on-goal right after Phase 1 PoC—BBB tech, in-vivo CAR-T, amylin, siRNA—to grow future blockbusters in-house.

Links below:
Spotify: open.spotify.com/episode/4eLk...

YouTube: youtu.be/dv7swppsavo?...

Apple: podcasts.apple.com/us/podcast/d...

5/5 Want to see how a government-led “Abundance Agenda” for biotech could reshape our industry? Read the full thought experiment here: bigpharmasharma.substack.com/p/biotech-cz...

#biotech #Biopharma #innovation #Abundance

5/5 Want to see how a government-led “Abundance Agenda” for biotech could reshape our industry? Read the full thought experiment here: bigpharmasharma.substack.com/p/biotech-cz...

#biotech #Biopharma #innovation #Abundance

4/5 We’d also launch a Cure Bounty Program and invest in robust biomarkers and global partnerships to ensure that breakthroughs reach patients faster and more safely.

3/5 My plan focuses on accelerating FDA reviews, redirecting capital toward bold, diverse ideas, and creating new initiatives like a “Warp Speed 2.0” for discovery, plus expanded talent, manufacturing, & trial networks.

2/5 Inspired by my read of @ezrakleinbot.bsky.social & @dkthomp.bsky.social 's new book, "Abundance", I conducted a thought experiment, pretending to be biotech czar, and crafted an agenda that rethinks our scarcity mindset and unlocks a future of rapid, transformative innovation in medicines.

The next few years will tell us if IPF is finally evolving—or if we’re doomed to another decade of disappointment.

📩 I break it all down in my latest deep dive—check it out here: bigpharmasharma.substack.com/p/a-crucial-...

💬 Who do you think has the best shot at breaking into this space?

With BI in the lead, who can challenge them? BMS, Pliant (if they recover), and a handful of other players (GSK, Lilly, AZ) are lurking. And let’s not forget the growing number of inhaled and reformulated Ofev/Pirfenidone and novel target plays that could reshape the standard of care.

Last week we saw:

✅ Boehringer Ingelheim’s nerandomilast delivers a second pivotal win (in PPF), ontop of positive data in IPF late last year

❌ Pliant’s bexotegrast study is paused - is this the beginning of yet another failure in IPF?

💰 Roche sells off Esbriet - this feels like a punt to me

And to my surprise, it was startling how little has changed since the days I was covering this space as a young professional. IPF continues to be a graveyard, but maybe we are starting to see some glimmers of hope.